| Literature DB >> 21474201 |
A Matsushima1, O Tasaki, K Tomono, H Ogura, Y Kuwagata, H Sugimoto, T Hamasaki.
Abstract
Healthcare-associated infection by meticillin-resistant Staphylococcus aureus (MRSA) is still a great concern in an intensive care unit (ICU). Our surveillance data in the ICU revealed that intubated patients were at eight times higher risk of acquiring MRSA than non-intubated patients, so we hypothesised that pre-emptive contact precautions for all intubated patients would prevent healthcare-associated infection by MRSA in the ICU. Patients staying in our ICU for >2 days were included in this study. The study period was divided into two periods. During 2004 (1st period), contact precautions were performed only for patients with MRSA. During 2005-2007 (2nd period), contact precautions were applied to all intubated patients regardless of MRSA infection status. Patients were defined as MRSA-positive on admission when MRSA was detected by surveillance or clinical culture on enrolment. Other MRSA-positive results were defined as healthcare-associated MRSA (HA-MRSA) transmission. HA-MRSA infection was diagnosed according to the National Nosocomial Infections Surveillance Manual. The 1st period comprised 415 patients, and the 2nd period comprised 1280 patients. In intubated patients, HA-MRSA infection rate decreased significantly in the 2nd period (1st period 12.2%, 2nd period 5.6%; P=0.015). HA-MRSA infection of all patients decreased from 3.6 to 2.3 incidents per 1000 patient-days (P<0.05), despite a significant increase in the rate of patients MRSA positive on admission in the 2nd period (1st period 2.9%; 2nd period 6.1%). Pre-emptive contact precautions for intubated patients would be helpful in reducing HA-MRSA infection in ICU.Entities:
Mesh:
Year: 2011 PMID: 21474201 PMCID: PMC7114861 DOI: 10.1016/j.jhin.2011.02.010
Source DB: PubMed Journal: J Hosp Infect ISSN: 0195-6701 Impact factor: 3.926
Precautions for preventing healthcare-associated infection in the 1st and 2nd periods
| Patients | Precautions | |
|---|---|---|
| 1st period (2004) | 2nd period (2005–2007) | |
| Intubated | Standard | Standard + contact |
| Non-intubated | Standard | Standard |
| MDRO+ | Standard + contact | Standard + contact |
MDRO+, positive for multidrug-resistant organisms.
Figure 1Schematic of the study. MRSA+, meticillin-resistant Staphylococcus aureus.
Patient characteristics
| 1st period | 2nd period | ||
|---|---|---|---|
| Age (years) | 50 ± 22 | 55 ± 22 | <0.05 |
| Sex (% male) | 68.4 | 63.1 | NS |
| No. of patients | 415 | 1280 | − |
| Patient-days | 5457 | 16 381 | − |
| Mean ICU stay (days) | 13 + 21 | 13 + 20 | NS |
| No. of intubated patients | 146 (35.2%) | 520 (40.6%) | <0.05 |
| No. of patients MRSA+ on admission | 12 (2.9%) | 78 (6.1%) | <0.05 |
NS, non-significant; ICU, intensive care unit; MRSA+, positive for meticillin-resistant Staphylococcus aureus.
Figure 2Percentage of healthcare-associated meticillin-resistant Staphylococcus aureus (HA-MRSA) transmission [colonisation (light grey bars) and infection (dark grey bars)] in intubated and non-intubated patient groups.
Details of the healthcare-associated meticillin-resistant Staphylococcus aureus infections
| Infection | 1st period | 2nd period |
|---|---|---|
| Pneumonia | 7 (1.69%) | 19 (1.48%) |
| Surgical wound | 5 (1.20%) | 6 (0.47%) |
| Bloodstream | 3 (0.72%) | 4 (0.31%) |
| Gastrointestinal | 3 (0.72%) | 1 (0.08%) |
| Central nervous system | 1 (0.24%) | 0 |
| Urinary tract | 0 | 3 (0.23%) |
| Sinusitis | 0 | 1 (0.08%) |
| Total no. of infections | 19 (4.58%) | 34 (2.66%) |
Figure 3Monthly healthcare-associated meticillin-resistant Staphylococcus aureus infection rates during the study period. Vertical line represents the time of intervention. Dotted line: non-intubated; dashed line: intubated; solid line: total.
Segmented Poisson regression analysis for pre-emptive contact precautions for intubated patients
| Variable | Coefficient | SE | 95% CI | χ2 | ||
|---|---|---|---|---|---|---|
| Lower | Upper | Statistic | ||||
| Intubated | ||||||
| Intercept | −0.85 | 0.41 | −1.65 | −0.06 | 4.40 | 0.0360 |
| Baseline trend | −0.29 | 0.10 | −0.48 | −0.09 | 8.49 | 0.0036 |
| Level change after intervention | −1.77 | 0.72 | −3.19 | −0.36 | 6.01 | 0.0142 |
| Trend change after intervention | 0.28 | 0.10 | 0.08 | 0.48 | 7.67 | 0.0056 |
| Non-intubated | ||||||
| Intercept | −4.24 | 1.22 | −6.63 | −1.86 | 12.16 | 0.0005 |
| Baseline trend | −0.04 | 0.17 | −0.37 | 0.29 | 0.05 | NS |
| Level change after intervention | −0.29 | 1.64 | −3.51 | 2.93 | 0.03 | NS |
| Trend change after intervention | 0.04 | 0.17 | −0.30 | 0.38 | 0.05 | NS |
| Total | ||||||
| Intercept | −2.90 | 0.48 | −3.83 | −1.96 | 36.83 | <0.0001 |
| Baseline trend | −1.56 | 0.65 | −2.83 | −0.28 | 5.74 | 0.0166 |
| Level change after intervention | −0.24 | 0.08 | −0.40 | −0.08 | 8.44 | 0.0037 |
| Trend change after intervention | 0.23 | 0.08 | 0.07 | 0.40 | 7.62 | 0.0058 |
| Intubation | 1.81 | 0.34 | 1.14 | 2.47 | 28.43 | <0.0001 |
CI, confidence interval; SE, standard error; NS, non-significant.
Cost (US$/year) for contact precautions and antibiotics used to treat meticillin-resistant Staphylococcus aureus infections
| 1st period | 2nd period | Change in cost | |
|---|---|---|---|
| Gloves + aprons | 49,242 | 71,493 | +22,251 |
| Antibiotics (IV + PO) | 40,628 | 28,932 | −11,696 |
| Total | 89,870 | 100,425 | +10,555 |
IV, intravenous; PO, per oral.